Zobrazeno 1 - 10
of 155
pro vyhledávání: '"Michael Szarek"'
Autor:
Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M. Bauersachs, Scott D. Berkowitz, Lloyd Haskell, Elliot S. Barnathan, Marc P. Bonaca
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 8 (2024)
Background The VOYAGER PAD (Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
Externí odkaz:
https://doaj.org/article/cb7732979fc142828382971a3178e404
Autor:
Kusha A. Mohammadi, Taylor Brackin, Gregory G. Schwartz, Philippe Gabriel Steg, Michael Szarek, Garen Manvelian, Robert Pordy, Sergio Fazio, Gregory P. Geba
Publikováno v:
Cancer Medicine, Vol 12, Iss 16, Pp 16859-16868 (2023)
Abstract Objective Assess the risk of new and worsening cancer events among participants who received the lipid‐lowering therapy alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor. Design Pooled post hoc analysis. Setting Six pha
Externí odkaz:
https://doaj.org/article/d27f08a8ad964f6d928013b081b6f41a
Autor:
Gaspard Suc, Gregory G. Schwartz, Shaun G. Goodman, J. Wouter Jukema, Garen Manvelian, Yann Poulouin, Robert Pordy, Michel Scemama, Michael Szarek, Ph. Gabriel Steg, ODYSSEY OUTCOMES Investigators
Publikováno v:
BMC Ophthalmology, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background Some data suggest that low levels of low-density lipoprotein cholesterol (LDL-C) are associated with risk of cataracts. Proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors reduce LDL-C below levels achieved with sta
Externí odkaz:
https://doaj.org/article/301a764a463e4ca39d6b0073ee2a3593
Autor:
Patrick R. Lawler, MD, MPH, Garen Manvelian, PhD, Alida Coppi, PhD, Amy Damask, PhD, Michael N. Cantor, MD, Manuel A. R. Ferreira, PhD, Charles Paulding, PhD, Nilanjana Banerjee, PhD, Dadong Li, PhD, Susan Jorgensen, MS, Richa Attre, PhD, David J. Carey, PhD, Kristi Krebs, PhD, Lili Milani, PhD, Kristian Hveem, MD, Jan K. Damås, PhD, Erik Solligård, PhD, Stefan Stender, MD, Anne Tybjærg-Hansen, MD, Børge G. Nordestgaard, MD, Tamara Hernandez-Beeftink, PhD, Tormod Rogne, MD, Carlos Flores, PhD, Jesús Villar, MD, Keith R. Walley, MD, Vincent X. Liu, MD, Alison E. Fohner, PhD, Luca A. Lotta, MD, Christos A. Kyratsous, PhD, Mark W. Sleeman, PhD, Michel Scemama, MD, Richard DelGizzi, MS, Robert Pordy, MD, Julie E. Horowitz, PhD, Aris Baras, MD, Greg S. Martin, MD, Philippe Gabriel Steg, MD, Gregory G. Schwartz, MD, Michael Szarek, PhD, Shaun G. Goodman, MD
Publikováno v:
Critical Care Explorations, Vol 5, Iss 11, p e0997 (2023)
OBJECTIVES:. Treatments that prevent sepsis complications are needed. Circulating lipid and protein assemblies—lipoproteins play critical roles in clearing pathogens from the bloodstream. We investigated whether early inhibition of proprotein conve
Externí odkaz:
https://doaj.org/article/9668af2bf04b4033991c97345adef80d
Autor:
Shaun G. Goodman, Philippe Gabriel Steg, Yann Poulouin, Deepak L. Bhatt, Vera A. Bittner, Rafael Diaz, Genevieve Garon, Robert A. Harrington, J. Wouter Jukema, Garen Manvelian, Wanda Stipek, Michael Szarek, Harvey D. White, Gregory G. Schwartz
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 12, Iss 18 (2023)
Externí odkaz:
https://doaj.org/article/e884e0e0649f4d2c9f494d28f4382e5d
Autor:
Deepak L. Bhatt, Michael Szarek, Bertram Pitt, Ph Gabriel Steg, on behalf of the SCORED Investigators
Publikováno v:
American Journal of Preventive Cardiology, Vol 13, Iss , Pp 100402- (2023)
Therapeutic Area: Diabetes Background: SGLT2 inhibitors have had a remarkable effect on heart failure, but variable effects on ischemic endpoints. In the SCORED trial, sotagliflozin, a dual SGLT1 and 2 inhibitor, reduced total cardiovascular (CV) dea
Externí odkaz:
https://doaj.org/article/bd83f3790f234f1fa8c5d467cdfc8c6f
Autor:
Gaspard Suc, Gregory G. Schwartz, Shaun G. Goodman, J. Wouter Jukema, Garen Manvelian, Yann Poulouin, Robert Pordy, Michel Scemama, Michael Szarek, Ph.Gabriel Steg, ODYSSEY OUTCOMES Investigators
Publikováno v:
BMC Ophthalmology, Vol 23, Iss 1, Pp 1-2 (2023)
Externí odkaz:
https://doaj.org/article/6488be9bd7fc4f7b883fa7c3b946e0ee
Autor:
Peter P. Toth, Gregory G. Schwartz, Stephen J. Nicholls, Aziz Khan, Michael Szarek, Henry N. Ginsberg, Jan O. Johansson, Kamyar Kalantar-Zadeh, Ewelina Kulikowski, Ken Lebioda, Norman C.W. Wong, Michael Sweeney, Kausik K. Ray
Publikováno v:
American Journal of Preventive Cardiology, Vol 11, Iss , Pp 100372- (2022)
Background: Nonalcoholic fatty liver disease (NAFLD) is common among patients with type 2 diabetes mellitus (T2DM) and is associated with increased risk for coronary atherosclerosis and acute cardiovascular (CV) events. We employed the validated, non
Externí odkaz:
https://doaj.org/article/291ad78b9b074af696eccafc0be2b3d5
Autor:
Connie N. Hess, Iris Baumgartner, Sonia S. Anand, Mark R. Nehler, Manesh R. Patel, E. Sebastian Debus, Michael Szarek, Warren Capell, Eva Muehlhofer, Scott D. Berkowitz, Lloyd P. Haskell, Rupert M. Bauersachs, Marc P. Bonaca, Judith Hsia
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 12 (2022)
Background Despite high female prevalence of peripheral artery disease (PAD), little is known about sex‐based outcomes after lower extremity revascularization (LER) for symptomatic PAD. The effects of rivaroxaban according to sex following LER have
Externí odkaz:
https://doaj.org/article/e206edcaf2794bc898a22f84d5fb18a2
Autor:
Michael Szarek, Connie Hess, Manesh R. Patel, W. Schuyler Jones, Jeffrey S. Berger, Iris Baumgartner, Brian Katona, Kenneth W. Mahaffey, Lars Norgren, Juuso Blomster, Frank W. Rockhold, Judith Hsia, F. Gerry R. Fowkes, Marc P. Bonaca
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 11 (2022)
Background Peripheral artery disease (PAD) is associated with heightened risk for major adverse cardiovascular and limb events, but data on the burden of risk for total (first and potentially subsequent) events, and the association with polyvascular
Externí odkaz:
https://doaj.org/article/18699052c2634fccb3f16e04b1efee27